For Quick Alerts
For Daily Alerts
Glenmark Pharma plans US clinical trials on biological drug
New Delhi, Sep 11 (UNI) Glenmark Pharmaceuticals today said it has filed for approval to start initial stage clinical trials of experimental biological drug GBR 500 with the US Food and Drug Administration (US FDA).
The drug is a monoclonal antibody, which Glenmark hopes to initially develop as a treatment for multiple sclerosis.
The company expects to complete the trials in the current financial year, it said in a statement.
UNI
AK
SY
KN1136
Comments
Story first published: Thursday, September 11, 2008, 12:04 [IST]